CCL5 and type 1 diabetes mellitus: The analysis revealed that in patients with type 1 diabetes (n = 42) CCL5 treated Tregs more efficiently suppressed the production of IFN-γ by effector T lymphocytes compared to Tregs “not-stimulated” with CCL5 (Fig. 6).